The Health and Economic Benefits Associated With Pneumococcal Vaccination of Elderly Persons With Chronic Lung Disease

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

“…26,60,61 Consequently in the current analysis, since our populations were aged ≥60 years, we considered a range of 0-42% effectiveness against NBPP for both populations in the sensitivity analyses (minimum and maximum State to data collection: one public hospital, Hospital São Paulo (HSP), and one private hospital, Hospital Israelita Albert Einstein (HIAE) were included. Both hospitals are among the largest in Sao Paulo, each with more than 500 beds (Fig.…”

“…This analysis was conducted in Sao Paulo State, diseases, vaccination with PPV23 is again more cost-effective or cost-saving compared to no vaccination strategy among the elderly, considering only direct medical costs. [24][25][26][27] This economic benefit increases with age of elderly targeted and vaccination of all individuals above the age 65 years is comparable in terms of cost-effectiveness to many accepted health care interventions. 27 The study's limitations were related to the various inputs used.…”

Vaccination in the prevention of infectious respiratory diseases in adults

“…Patients with COPD should receive vaccination against influenza 87-89 (B), which reduces mortality in 41% of cases 89 (B). There is a benefit to the combined use of flu and pneumococcus vaccines with the reduction of hospitalizations, pneumonia and mortality [90][91][92] (B), though the reduction in mortality is influenced more by the protection of the flu vaccine 89.93 (B). The use of PCV7 has led to a reduction in the IPD rate in children under 5 with sickle cell anemia, with a reduction in IPD in 93.4% of cases.…”

Additive preventive effect of influenza and pneumococcal vaccines in the elderly

“…In 2005, the French national health authorities 4 recommended pneumococcal vaccination every 5 y for elderly people only if they are at high risk of pneumococcal invasive infections (e.g., chronic organ failure, immunodepression, diabetes) or when they are being admitted in institutions. 4,9 Efficacy of pneumococcal vaccine to prevent pneumococcal bacteremia and pneumonia in elderly people has been shown in case-control [10][11][12][13][14] and cohort [15][16][17] studies. In contrast, prospective randomized studies have benefits.…”